|
|
|
Published: 2024-06-28 12:05:00 CEST
|
Gubra A/S
Managers' Transactions
|
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company") hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.
|
1.
|
Details of the person discharging managerial responsibilities/person closely associated
|
|
a)
|
Name
|
Monika Lessl
|
|
2.
|
Reason for the notification
|
|
a)
|
Position/status
|
Board member in Gubra
|
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Gubra A/S
|
|
b)
|
LEI
|
254900T17RRFZONO6W53
|
|
4.1
|
Details of the transaction(s):
|
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Shares
ISIN DK0062266474
|
|
b)
|
Nature of the transaction
|
Purchase
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
DKK 478
|
306
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Average price per share: DKK 478
Total number of shares: 306
Total price: DKK 146,268
|
|
e)
|
Date of the transaction
|
28 June 2024
|
|
f)
|
Place of the transaction
|
NASDAQ Copenhagen A/S
|
About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See www.gubra.dk for more information.
This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-06-28 12:05 CEST.
|
|
Attachments:
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra AS shares.pdf
|
|
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
|
|
Gubra A/S